Superworth

Fortrea FTRE

Medical - Diagnostics & Research, Healthcare
$20.02
−5.97%
Market cap
$1.9B
PE
n/m
one or more of the four quarters through 2026-09-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
0.7×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$2.7B
−3% on a year ago
Net margin
−2.6%
Free cash flow yield
8.7%

Fortrea trades at 0.7× sales. Revenue was $2.7B over the last twelve months, down 3% on a year earlier with a −3% net margin.

Charts

Financials

Income statement for FTRE, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$709.7M−7%$662.1M−5%$662.4M−9%$674.9M−5%$697M−2%$651.3M−2%$710.3M+7%$701.3M+4%$660.5M−5%$636.5M−2%$678.2M−5%$691.5M−1%
Cost of revenue$577.9M−4%$554.2M+2%$525.3M−8%$526.6M−7%$556.1M−4%$534.8M−4%$576.8M+10%$578.6M+10%$529.4M−5%$512.9M−4%$539M−7%$552M−5%
Gross profit$131.8M−19%$107.9M−29%$137.1M−12%$148.3M−1%$140.9M+7%$116.5M+8%$133.5M−3%$122.7M−17%$131.1M−7%$123.6M+6%$139.2M+4%$139.5M+14%
SG&A$126.7M+100%$120.1M+3%$156.2M+60%$136.3M+28%$148.1M+17%$121.8M+1%$124.8M−20%$106.8M−22%$103M−31%$100.5M−18%$102.1M−18%$103.8M−3%
−$24M−$37.4M−$50.9M−$18M−$55.6M+132%−$520.1M+1291%−$330.3M+549%−$8.6M−52%−$13.6M−76%−$3.4M−99%$14.8M$15M
Interest expense$34.5M+17150%$34.3M+34200%$45.2M+6357%$22.4M−35%$21.9M−37%$22.3M−35%$23.3M−49%$22.6M+1%$23.2M+6%$19.1M−14%$19.3M−17%$20.2M−11%
Pre-tax income−$54.7M−$75.7M−$88.6M−$35.8M+64%−$74.9M+37%−$548M+624%−$370.7M+318%−$28.7M−20%−$35.6M−53%−$12.3M−98%−$1.2M−100%−$3.6M−88%
−$6.1M$4.1M+173%$10.7M−8%−$17.3M+198%−$1M−84%$14.9M+263%$4.2M−61%−$12.8M−26%−$3.1M+210%$11.3M−24%$12M+186%−$4.2M−67%
Net income−$54.5M−$101M−$138.4M−$27.9M+99%−$61.2M+12%−$562.9M+457%−$374.9M+171%−$15.9M−43%−$32.5M−47%−$23.6M−96%−$13.2M−97%$600K
−$0.61−$1.13−$1.55−$0.31+94%−$0.68+12%−$6.25+453%−$4.14+167%−$0.17−45%n/a−$0.25−96%−$0.14−97%$0.01
88.8M+0%89.2M+1%89.4M+1%89.6M+1%89.8M+1%90.1M+1%90.6M+1%91.2M+2%n/a93.6M+4%94.8M+5%101.2M+11%

Revenue: Q1 FY22: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY22: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY22: 6 months less the 3 months printed beside them. 18 periods, Q2 FY22 to Q3 FY26: not printed by the filing, worked out from its own lines.

SG&A: Q1 FY22: 6 months less the 3 months printed beside them.

Operating income: Q1 FY22: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY22: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY22: 6 months less the 3 months printed beside them.

Income tax: Q1 FY22: 6 months less the 3 months printed beside them.

Net income: Q1 FY22: 6 months less the 3 months printed beside them.

EPS, diluted: 4 periods, Q1 FY22 to Q4 FY24: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY22 and Q1 FY23: share-days: the 6-month average less the second quarter's. Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
FTREFortrea$1.9Bn/mn/a0.7×−3%−2.6%
VCYTVeracyte$3.9B35.0×66.2×7.0×+17%20.4%
CDNACareDx$4.5B35.9×19.2×9.1×+39%25.9%
BLLNBillionToOne$5.2B170×152×13.1×+90%9.5%
LNTHLantheus$6.5B24.3×24.0×4.2×+2%17.7%
NRCNRC Health$536.6M97.0×35.2×3.8×−0%4.2%
CAICaris Life Sciences$9.1B86.8×78.4×9.2×+85%10.6%
BIOBio-Rad Laboratories$9.8B44.4×30.9×3.8×+1%8.6%
RVTYRevvity$16.9B72.2×35.1×5.8×+4%8.2%
MEDPMedpace$18.1B38.0×34.5×6.5×+25%17.7%
Peer median$6.5B44.4×35.1×6.5×+17%10.6%

More on Fortrea

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .